Drugs Of Abuse Testing Market Size, Share and Global Trend By Product (Equipments, Consumables), By Sample Type (Saliva, Urine, Hair, Breath, Blood, Sweat), By Application (Medical Screening, Monitoring Pain Management, Forensic & Legal Information, Employment Drug Testing, Sports & Athletics Testing), By End User (Hospital, Forensic Labs, Diagnostic Centres, Speciality Clinics) and Regional Forecast, 2024-2032

Drugs of abuse are illegal drugs used for the non-medication purpose for a longer duration of time. The qualitative tests performed to detect the presence of the illicit drug in the samples such as urine, blood, saliva, or breath are defined as drugs of abuse testing. Use of narcotic drugs is harmful to the body and is also an economic and social burden. Some of the commonly screened drugs are amphetamine, marijuana, opiates, methadone, barbiturates, and others.

Many rapid and on-spot are now available for the testing of drug-abusing. For example, in 2018, the FDA approved OralTox, a rapid oral fluid testing device manufactured by Premier Biotech, Inc. for testing of multiple drugs simultaneously. This device demonstrated greater accuracy than other methods and provided results in less than two hours. These growing technological advancements in drug abuse screening is likely to upsurge the growth of drugs of abuse testing market during the forecast period.

To gain extensive insights into the market, Request for Customization

Growing technological advancements in analyzers for multidrug detection at a single run, the growing trend of employment medical screening, and growing investments by many key players in developing novel products for drug abuse screening are likely to boost the growth of drugs of abuse testing market during the forecast period. Additionally, enforcement of stringent regulations by the government making drug abuse screening mandatory is likely to fuel the growth of drugs of abuse testing market during the forecast period

However, lack of awareness about drug abuse testing methods in underdeveloped countries is likely to hamper the growth in global drugs of abuse testing market during the forecast period.

Key Players Covered

Some of the major companies that are present in the global drugs of abuse testing market are Siemens Healthcare GmbH, Abbott, Thermo Fisher Scientific Inc., LifeSign LLC., MP Biomedicals, Premier Biotech, Inc., MEDACX Ltd., Chromsystems Instruments & Chemicals GmbH, AccuBioTech Co. Ltd., Screen Italia Srl, Paramedical s.r.l., and others.

SEGMENTATION

Among product segmentation, consumables segment is anticipated to account for the largest share of global drugs of abuse testing market during the forecast period owing to the increased availability of one-step dip cards, strips, cassettes and multidrug panels for drug abuse testing which in turn aids in the reduction of the time of testing when compares to other methods.

Key Insights

• Regulatory Scenario for Key Countries/Regions
• Technological Advancements in Drug Abuse Testing Methods
• Overview of Number of Illicit Drug Abusers
• Recent Industry Developments Such as Partnerships, Mergers, and Acquisitions

Regional Analysis

In terms of region, the global drugs of abuse testing market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America, is anticipated to dominate the drugs of abuse testing market during the forecast period owing to the strict law enforcement for the use of prohibited drugs and increased availability of on-spot testing kits. Additionally, the drugs of abuse testing market is projected to grow at significant rate in Asia Pacific region during the forecast period owing to upsurge in number of youngsters addicted to illicit-drugs and growing awareness by government organizations about the health consequences related to the use of illicit drugs and new technological advances in drugs of abuse testing methods.

Key Industry Developments

• In May 2018, Phenomenex Inc. announced the launch of Strata-X-Drug B Plus, a product for Solid Phase Extraction(SPE) sample preparation to be used for urine testing in forensic and clinical labs.
• In August 2018, the FDA granted 510 (k) approval to OralTox, a rapid oral fluid testing device manufactured by Premier Biotech, Inc. for testing of 8 different drugs.
• In July 2017, Immunalysis Corporation, a division of Abbott received 510 (k) approval from FDA for SEFRIA™ Fentanyl Urine Enzyme Immunoassay, which can be used to detect fentanyl in the urine.